Core Viewpoint - The market is expected to enter a "low season" mode due to the impact of the National Day and Mid-Autumn Festival holidays, along with uncertainties surrounding the U.S. government's short-term financing bill and potential overseas disturbances [1] Market Conditions - There is still divergence in the market regarding the timing and extent of interest rate cuts by the Federal Reserve [1] - Some quality sectors in the Hong Kong stock market have valuations close to historical highs, leading to short-term profit-taking pressure [1] Investment Strategy - The company recommends maintaining a "high elasticity" and "high dividend" barbell strategy for industry allocation, with appropriate adjustments based on policy catalysts [1] - Selected stocks for October include: Qifu Technology, Prosperity Industrial Trust (00778), OmniVision Technologies, Kuaishou-W (01024), Alibaba-W (09988), China National Heavy Duty Truck Group (03808), CanSino Biologics (09926), Pop Mart International (09992), and China Power (02380) [1] Sector Insights - Driven by technological narratives, there is a continuous increase in domestic and international computing power investments [1] - The demand from domestic investors for quality Hong Kong stocks in the AI sector remains strong [1]

Core Viewpoint - Aimeson has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors being CCB International and Bank of Communications International [1] Company Summary - Aimeson is a leading early cancer detection company focused on high incidence and high mortality cancers, having developed a methylation-based early cancer detection technology [1] - The company's core products include Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with Aixin Gan being the world's first liver cancer detection reagent based on methylation and qPCR technology, achieving a sensitivity of 84.43% for stage I liver cancer [1] - Aiguang Le allows for non-invasive detection of urinary tract cancer using just 1 milliliter of urine, enhancing efficiency and convenience [1] - Aimeson has a comprehensive early cancer detection platform covering multiple cancers, including colorectal, liver, esophageal, urinary tract, gastric, lung, and gynecological cancers, and is developing several combination detection reagents [1] Industry Summary - The Chinese tumor molecular testing market is rapidly growing, with an expected market size of 38.8 billion RMB by 2033 [1] - Aimeson employs cost-effective qPCR technology combined with proprietary iTBFinder platform, AS-Cap technology, and SEM-PCR technology to enhance detection capabilities [1] - The company is developing an automated sample processing workstation, AMStation, to support large-scale testing [1]

Group 1: Alibaba Group - CMB International maintains a "Buy" rating for Alibaba-SW, raising the target price to HKD 195, citing advancements in AI infrastructure investment of RMB 380 billion and a projected 10x increase in data center energy consumption by 2032 [1] - CICC also maintains an "Outperform" rating for Alibaba-SW, increasing the target price to HKD 197, highlighting the leading position of Tongyi model ecosystem and the potential for commercial value release [1] Group 2: Kuaishou Technology - UBS maintains a "Buy" rating for Kuaishou-W, setting a target price of HKD 95.37, noting significant advancements in the 可灵 2.5 Turbo model for text understanding and video generation [1] Group 3: Xiaomi Corporation - Daiwa Securities maintains a "Buy" rating for Xiaomi Group, with a target price of HKD 76, reporting an increase in weekly electric vehicle deliveries to 10,000-12,000 units and plans to enter the European market by 2027 [2] Group 4: Longwind Pharmaceutical - China Everbright Securities International highlights Longwind Pharmaceutical's strong growth prospects, focusing on inhalation technology and drug development, with six products approved in the respiratory disease field [3] Group 5: Nine Dragons Paper Holdings - Bank of America maintains a "Buy" rating for Nine Dragons Paper, setting a target price of HKD 6.5, with a projected net profit of RMB 1.767 billion for FY25 and a 9.7% increase in sales [3] - Shenwan Hongyuan also maintains a "Buy" rating, noting significant improvements in gross profit and net profit, with expected growth in net profit for 2026-2028 [4] - Guotai Junan raises the target price for Nine Dragons Paper to HKD 7.37, citing a 9.6% increase in sales and a 1.9 percentage point rise in gross margin [4] Group 6: Xindong Company - CMB Securities strongly recommends Xindong Company, highlighting the successful public testing of "伊瑟" and a 37.74% increase in revenue from the TapTap platform [5] Group 7: Mixue Group - CITIC Securities maintains a "Buy" rating for Mixue Group, emphasizing its efficient supply chain and membership growth exceeding 300 million, with plans for expansion in Southeast Asia and new global markets [6]

Core Viewpoint - The Hang Seng Healthcare Index fell by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Recommendations - The report suggests focusing on companies with significant data releases at the upcoming ESMO conference in mid to late October, specifically mentioning Kangfang Biotech (09926), Kelun-Biotech (06990), and Rongchang Biotech (09995) [1] - The importance of timing and stock selection has increased following a broad rise in the innovative drug sector, with recommendations to gradually build positions during market corrections [1] Group 3: Sector Focus - For the innovative drug sector, the report highlights companies such as 3SBio (01530) and Eucure Biopharma-B (06996) as having rich short-term catalysts and undervalued core products, while companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are noted as significantly undervalued with clear long-term growth logic [1] - In the CXO sector, the report points to leading companies benefiting from high downstream demand and marginal recovery in financing, specifically mentioning WuXi AppTec (02268) [1]

Core Viewpoint - The Hang Seng Healthcare Index declined by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Opportunities - Domestic investors are focusing on rebound opportunities, while foreign investors are increasing positions in innovative drug targets with high long-term potential and current cost-effectiveness [1] - The innovative drug guarantee model is gradually taking shape, which is expected to alleviate challenges such as hospital access and reimbursement difficulties for companies [1] Group 3: Upcoming Events - The ESMO conference will be held in mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] Group 4: Stock Recommendations - The importance of timing and stock selection has increased after a broad rise in the innovative drug sector, with recommendations to gradually build positions during sector pullbacks [1] - Specific recommendations include: 1. Innovative drugs: 3SBio (01530), Eucure Biopharma-B (06996) with rich short-term catalysts and undervalued long-term growth logic [1] 2. CXO: Leaders in high-demand segments benefiting from improved financing conditions, such as WuXi AppTec (02268) [1]

格隆汇9月25日丨交银国际(03329.HK)宣布，伊莉于2025年9月27日起辞任公司公司秘书及公司授权代 表。同日宣布，曾佳荔已获委任为公司公司秘书及授权代表，自2025年9月27日起生效。 ...

曾佳荔女士已获委任为公司公司秘书及授权代表，自2025年9月27日起生效。 交银国际(03329)发布公告，伊莉女士于2025年9月27日起辞任公司公司秘书及公司授权代表(根据香港联 合交易所有限公司证券上市规则第3.05条规定)。 ...

智通财经APP讯，交银国际(03329)发布公告，伊莉女士于2025年9月27日起辞任公司公司秘书及公司授 权代表(根据香港联合交易所有限公司证券上市规则第3.05条规定)。 曾佳荔女士已获委任为公司公司秘书及授权代表，自2025年9月27日起生效。 ...

公司秘書及授權代表變更 公司秘書及授權代表辭任 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 （於香港註冊成立的有限公司） （股份代號：3329） 交銀國際控股有限公司 交銀國際控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）宣佈，伊莉女士（「伊 女士」）於2025年9月27日起辭任本公司公司秘書（「公司秘書」）及本公司授權代表（根據 香港聯合交易所有限公司（「聯交所」）證券上市規則第3.05條規定）（「授權代表」）。伊女 士已確認，彼與董事會並無意見分歧，亦無有關其辭任的事宜須提請本公司股東或聯交 所垂注。 委任公司秘書及授權代表 董事會欣然宣佈，曾佳荔女士（「曾女士」）已獲委任為本公司公司秘書及授權代表，自 2025年9月27日起生效。 曾女士的履歷詳情載列如下： 曾女士於2017年11月加入本公司，彼自2011年1月起從 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 （於香港註冊成立的有限公司） （股份代號：3329） 持續關連交易 修訂現有金融服務框架協議項下的年度上限 茲提述相關披露，內容有關（其中包括）現有金融服務框架協議。 於2025年9月25日，董事會決議將證券經紀結算及認購新股截至2025年12月31日止年 度的年度上限提高至80.5百萬港元，而現有金融服務框架協議項下其餘交易截至2025 年12月31日止年度的年度上限將維持不變。 於本公告日期，交通銀行為持有已發行股份約73.14%的最終控股股東，故為本公司的 關連人士。因此，根據上市規則第14A章，現有金融服務框架協議項下擬進行的交易 構成本公司的持續關連交易。根據上市規則第14A.54條，本公司必須在現有金融服務 框架協議項下的現有年度上限被超出前重新遵守公告及獨立股東批准的規定。 由於 ...